Venipharm, a Privately-Owned French Pharmaceutical Company Founded in 1999
The Group's Pharmaceutical Focus
Venipharm has historically been a generic and biosimilar developer company, providing its technical, regulatory and commercial expertise to other pharmaceutical manufacturers to enable them to benefit from quality product sourcing. Venipharm has maintained since its beginning a strong partnership with leading manufacturers of active ingredients and medicines. Venipharm has obtained more than 400 MA from its own developments or from co-developments with major suppliers recognised worldwide. Benefiting from this vast experience, Venipharm is now expanding its expertise in the field of health and medicine by launching its own range of generic, biosimilars and niche drugs.
Our Vision
We aim and achieve operational excellence in all aspects of the quality and safety of our medicines, reducing lead times and costs. To achieve this, we draw on the expertise and know-how that has been built over many years. This makes us unique.
Our Mission
Developing Essential Therapeutic Solutions
We recognize and acknowledge the multidimensional challenges that healthcare organizations have to manage. Challenges are both Clinical and economical, with each day healthcare professional are having to face significant economic and medical challenges. Venipharm's aim and business model enables us to guarantee the sustainability of our healthcare system and maintain the availability of medicines, including the most essential ones. Our approach ensures that our expertise can be accessed by our partners, meeting their needs, optimising and supporting healthcare professionals and uncompromising quality of care for our patients.
Our Values
The success of our organisation is based on a dynamic, multidisciplinary team including but not exclusive to chemists, pharmacists and engineers specialising in pharmaceutical development. With their proven expertise, each member of our team has helped to consolidate the reputation of our brand with our customers and partners over the last 25 years. Our Patient Centric approach puts the patient at the centre of our thinking and integrates his or her specific needs into the choice of our decisions to guarantee the best quality of care. We focus all our efforts on identifying essential products to develop and market in order to optimise access to generic and biosimilar medicines.
Innovation
We continuously review and challenge all stakeholders involved in the manufacture of our products to integrate and consider innovation, social and environmental issues in both the production chain and day-to-day practices.
Commitment
We are deeply committed to the concept of vertical integration, with the aim of controlling both the production chain and production costs. We take care to comply with EU certifications when choosing our suppliers of active ingredients and finished products.
Expertise
With over 25 years' experience in pharmaceutical development, we remain committed to our professionalism values with our partners and distributors. This expertise has strengthened the trust they place in us, increasing Venipharm's presence and status as a “trusted Partner” throughout the Pharmaceutical Industry.
Integrity
At Venipharm, we value teamwork and communication. We actively encourage and engage in self-analysis critical review through reflective thinking. This is incorporated in daily interaction between the various departments within our company, and with our customers and suppliers. We firmly believe that this approach and mind set contributes to better analysis of situations, clear decision-making and effective problem-solving.
Social Responsibility
In 2024, we created more than 10 new jobs and began marketing our products to hospitals in France. Our aim is to meet the needs of our healthcare institutions, by partnering and supplying of medicines that come from a sustainable approach at an affordable price.
00
Million syringes sold worldwide
000+
MA obtained in Europe
00
Products under development
00
Growth by 2024
0000
Operator status obtained
00
Countries worldwide
Our History
Since Venipharm’ arrival in 1999, we have achieved a proven track record in the market. Venipharm has positioned itself as a true expert interface for stakeholders in the pharmaceutical sector, ensuring the worldwide development of affordable, high-quality pharmaceutical products. With an impeccable reputation and a unique value proposition, we have built up a strong portfolio of loyal partners that we continue to develop through our knowledge of the specific needs of each market. We not only believe but have demonstrated that the scope of our complementary core competencies ensures long-term success for our customers.
- 1999
- 2000
- 2010
- 2019
- 2021
- 2022
- 2023
- 2024
- 2025
Creation of the Venipharm Germany Subsidiary
Venipharm begins a new chapter with expansion into other European markets. Based in Hamburg, the subsidiary was created to coincide with the launch of Enoxaparin pre-filled syringes in Germany.
Creation of Venipharm France
Venipharm was founded at the end of the 90s in Saint-Cloud and began its pharmaceutical development activities.
1st MA Obtained in France
1st pharmaceutical dossier developed in France by Venipharm
100th MA Obtained in France
Venipharm continues to grow, obtaining its 100th Marketing Authorisation and becoming a specialist company approached by major pharmaceutical companies.
Creation of the Venipharm Germany Subsidiary
Venipharm begins a new chapter with expansion into other European markets. Based in Hamburg, the subsidiary was created to coincide with the launch of Enoxaparin pre-filled syringes in Germany.
Launch of Our 1st Biosimilar in Germany: Enoxaparin
In addition to pharmaceutical development, Venipharm extends its activities to the marketing of its flagship product ‘Enoxaparin’.
Venipharm France Becomes an Operating Company,
marking its commitment to developing the Venipharm brand in France.
Venipharm France Launches ‘Métopimazine’ in Retail
1st speciality launched in the Retail market under the Venipharm brand.
Venipharm LTD UK Sets Up its Operating Address in June
Continuing to support the aim of Venipharm Ltd in developing Market access and commercial activities to support essential medical needs treated by Venipharm's portfolio.
Venipharm France Launches Enoxaparin in Hospital
Diversification of the business with the launch of the Hospital Business Unit
Global Presence, Local Impact
Our Health Commitment
Our CSR Commitment
As a pharmaceutical company committed to sustainable development, Venipharm is involved to providing sustainable medicines and has set targets in this area. Our ambition is to continuously improve our own value chain by working with suppliers and service providers who are legally and ethically compliant, and who assess, monitor and reduce their environmental footprint. For Venipharm, ensuring a sustainable supply of finished products, materials and services is not just about complying with regulations; it is also about integrating social, ethical and environmental performance criteria into the supplier selection process, to be compliant to international principles of good business practice and our customers' requirements.
The 3 Topics of this Approach
Measuring Our Social and Environmental Impact
As part of our CSR roadmap, we have undertaken to be periodically audited by a third party to improve our performance and to identify our strengths in Environment, Social and Human Rights, Ethics and Responsible Purchasing areas.
Be Part of a Continuous Improvement Process
Use our regular audits to draw up action plans and set targeted objectives and performance indicators, particularly in terms of Responsible Purchasing, as part of our continuous improvement approach.
Ensuring the CSR Commitments of Our Stakeholders
As part of our Responsible Purchasing policy, we ensure that the partners, manufacturers and service providers with whom we work are committed to a CSR approach and set themselves high social and environmental objectives.
From Strategy to Action
The product life cycle and carbon impact are at the heart of our thinking for each Venipharm product launched on the market. We are fully aware of the need to incorporate the calculation standards and assessment criteria defined by our national institutions for our medicines. We are also strongly committed to the concept of vertical integration and EU and FDA certified facilities when choosing our suppliers of finished products. The aim of vertical integration is to locate sourcing and manufacturing in the same country in order to reduce the carbon impact of the finished product.
Ecovadis Assessment
In 2024, Venipharm's CSR commitments were evaluated by Ecovadis. Venipharm was awarded a bronze medal, placing it in the Top 35 best-rated companies. The aim of this assessment was to provide Venipharm with a starting point for its eco-responsible approach, so that it could rate its sustainable development management system. The Ecovadis assessment covered 21 CSR criteria divided into 4 topics:
- Environmental
- Social & Human Rights
- Ethics
- Responsible Purchasing
